Bioatla (BCAB) Q1 2025 earnings summary

Executive summary

• Advanced multiple CAB platform clinical programs, including BA3182, Mecbotamab vedotin, and Ozuriftamab vedotin, with strong early efficacy and survival data in solid tumors and ongoing internal and partnership-focused assets.

• Phase I dose escalation study of dual CAB EpCAM and CD3 T cell engager progressing well, with no maximally tolerated dose reached and multiple patients showing tumor reduction and prolonged therapy tolerance.

• Mecbotamab vedotin demonstrated 2-year landmark survival of 59% in mKRAS NSCLC, far exceeding standard of care outcomes.

• Ozuriftamab vedotin showed a 45% overall response rate and 100% disease control rate in HPV+ SCCHN, with Fast Track Designation for Phase 3 discussions.

• Workforce reduction and restructuring implemented in March 2025 to align resources with prioritized programs and improve cost structure.

Financial highlights

• R&D expenses decreased to $12.4 million for Q1 2025 from $18.9 million in Q1 2024, mainly due to lower clinical development costs and workforce reduction.

• G&A expenses were $5.3 million, down from $5.6 million year-over-year, reflecting lower stock-based compensation and insurance premiums.

• Net loss for Q1 2025 was $15.3 million, improved from $23.2 million in Q1 2024.

• Net cash used in operating activities was $16.3 million, down from $30.8 million in the prior year period.

• Cash and cash equivalents stood at $32.4 million as of March 31, 2025, compared to $49 million at year-end 2024.

Outlook and guidance

• R&D expenses expected to continue decreasing in 2025 due to restructuring and focus on prioritized programs.

• Sufficient cash runway anticipated to fund operations and achieve key clinical milestones through 1H 2026, excluding new partnerships, but substantial doubt exists about the ability to continue as a going concern without additional capital.

• Anticipated mid-2025 data readout for dose escalation of EpCAM/CD3 program and first half 2026 for cohort expansion and phase II data.